Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan Oral Solution in Pediatric Hypertension
NCT06863987Phase 3Enrolling by invitation
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valsartan in essential hypertension, sponsored by Shandong New Time Pharmaceutical. Started Feb 2025; status: enrolling by invitation.
02
Drugs
valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06863987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863987.